Compare GSK plc (GSK) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs KraneShares Hang Seng TECH Index ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while KraneShares Hang Seng TECH Index ETF trades at $11.81 (market cap $45.04M). The key difference: GSK plc is far larger — about 2040× KraneShares Hang Seng TECH Index ETF's market cap, and GSK plc pays a 3.9% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and KraneShares Hang Seng TECH Index ETF for 44 Days on average.
| GSK | KTEC | |
|---|---|---|
Market Cap | $91.88B | $45.04M |
Volume | 7,730,529 | 29,043 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $18.36 |
52-Week Low | $43.24 | $11.41 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
KTEC trades at $11.81, up 1.99% with bearish technical signals from moving averages. The company reported $120.04M revenue in 2016 with improving net margin (-0.59% vs -4.88% in 2015) and positive operating cash flow of $5.81M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC shows operational improvement but faces profitability challenges with negative net income. The stock's technical weakness and volatile earnings history suggest cautious approach. Upside depends on sustained revenue growth and margin expansion in competitive tech ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
